HD 18.

Trial name or title	HD18 for advanced stages in HL
Methods	Study design: All participants receive two cycles of BEACOPPesc and an additional PET scan PET‐negative PET‐adapted arm 2 further cycles of BEACOPPesc Standard arm 6 further cycles of BEACOPPesc PET‐positive PET‐adapted arm 6 further cycles of BEACOPPesc plus rituximab Standard arm 6 further cycles of BEACOPPesc
Participants	Age 18‐60 years Gender Both Inclusion criteria HL (histologically proven) CS IIB with one or both of the risk factors bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter) extranodal involvement CS III, IV Written informed consent Country Germany
Interventions	Chemotherapy BEACOPPesc Rituximab FDG‐PET
Outcomes	Progression‐free survival (5 years) Overall survival (5 years) Acute toxicity (5 years) Late toxicity (5 years) Complete remission rate (5 years)
Starting date	May 2008
Contact information	Michael Fuchs GHSG@uk‐koeln.de
Notes	Estimated enrolment: 1500 Estimated primary completion date: May 2012 Study status according to ClinicalTrials.gov: this study is currently recruiting participants